(function(){
			var content_array=["<p><sup><sup>[1]<\/sup><\/sup> Eye (2021) 35:1305–1316<br \/><sup><sup>[2]<\/sup><\/sup> Faricimab is the first bispecific antibody&nbsp; designed for intraocular use. In <span class=\"xn-chron\">January 2022<\/span> faricimab received its first&nbsp; approvals（Drugs (2022) 82:825–830 https:\/\/doi.org\/10.1007\/s40265-022-01713-3）<br \/><sup><sup>[3]<\/sup><\/sup> World Health Organization. Blindness and vision impairment.[Internet; cited <span class=\"xn-chron\">April 2022<\/span>]. Available from: <a href=\"https:\/\/t.prnasia.com\/t\/OnLPUxZs\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment<\/a>&nbsp;&nbsp;<br \/><sup><sup>[4]<\/sup><\/sup> <a href=\"https:\/\/t.prnasia.com\/t\/TLpacx3u\" target=\"_blank\" rel=\"nofollow\">https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/328717\/9789240008564-chi.pdf<\/a><br \/><sup><sup>[5]<\/sup><\/sup> Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J\/OL]. Diabetes Res Clin Pract, 2022, 183: 109119[2021-12-06]. <a href=\"https:\/\/t.prnasia.com\/t\/NtJbYgbG\" rel=\"nofollow\">https:\/\/pubmed.ncbi.nlm.nih.gov\/34879977\/<\/a>. DOI: 10.1016\/j.diabres.2021.109119.<br \/><sup><sup>[6]<\/sup><\/sup> Tan GS, Cheung N, Sim&oacute; R, et al. Diabetic macular oedema[J]. Lancet Diabetes Endocrinol, 2017, 5(2): 143-155. DOI: 10.1016\/s2213-8587(16)30052-3.<br \/><sup><sup>[7]<\/sup><\/sup> Khanani AM et al. Faricimab in nAMD and DME:Lates Updates Presented at the Anglogenesis, Exudation, and Degeneration 2023 Virtual Congress. February 10-11,2023.<br \/><sup>[8]<\/sup> 法瑞西单抗治疗糖尿病黄斑水肿的有效性、持久性和安全性：Ⅲ期RHINE研究中国亚组人群1年研究结果<\/p> \n<p>&nbsp;<\/p>"];
			$("#dvExtra").html(content_array[0]);})();